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Abstract
Purpose To assess the role of single-photon emission comput-
ed tomography with computed tomography (SPECT-CT) for
the identification of sentinel lymph nodes (SLNs) in patients
with early stage (T1–T2) oral cancer and a clinically negative
neck (cN0).
Methods In addition to planar lymphoscintigraphy, SPECT-
CTwas performed in 66 consecutive patients with early stage
oral cancer and a clinically negative neck. The addition of
SPECT-CT to planar images was retrospectively analyzed
for the number of additional SLNs, more precise localization
of SLNs, and importance of anatomical information by a team
consisting of a nuclear physician, surgeon, and investigator.
Results Identification rate for both imaging modalities com-
bined was 98% (65/66). SPECT-CT identified 15 additional
SLNs in 14 patients (22%). In 2/15 (13%) of these additional
SLNs, the only metastasis was found, resulting in an
upstaging rate of 3% (2/65). In 20% of the patients with at
least one positive SLN, the only positive SLN was detected
due to the addition of SPECT-CT. SPECT-CTwas considered
to add important anatomical information in two patients (3%).
In 5/65 (8%) of the patients initially scored SLNs on planar
lymphoscintigrams were scored as non-SLNs when SPECT-
CT was added. There were four false-negative SLN biopsy
procedures in this cohort.
Conclusions The addition of SPECT-CT to planar
lymphoscintigraphy is recommended for the identification of
more (positive) SLNs and better topographical orientation for
surgery in sentinel lymph node biopsy for early stage oral
cancer.
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Introduction
Sentinel lymph node biopsy (SLNB) in early stage oral cancer
is increasingly accepted as standard of care for staging of
occult lymph node metastasis. Trials in which only neck dis-
section is performed after positive SLNB have demonstrated
that SLNB is a sensitive method for the detection of occult
cervical lymph node metastases. A pooled sensitivity of 91%
(95% CI 84–95%) and a negative predictive value of 92–98%
were found in a meta-analysis [1], however some lower sen-
sitivity rates had been reported in recent large studies [2, 3]. In
most studies, the procedure had a lower accuracy in patients
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with floor-of-mouth tumors, probably due to the Bshine-
through phenomenon^; the large injection spot of the primary
tumor overshines the eventual sentinel lymph nodes (SLNs) in
level I.
Visualization of SLNs is routinely carried out with dynam-
ic and static planar lymphoscintigraphy using a 99mTc-labeled
colloidal tracer frequently combined with a blue dye intraop-
eratively. In our institute, single-photon emission computed
tomography with computed tomography (SPECT-CT) is rou-
tinely performed. After introduction of the SPECT-CT for
SLNB in oral cancer in 2003 by Even-Sapir et al. [4], most
studies conclude that SPECT-CT enhances useful information
in localization of the SLNs and provides additional SLNs as
described in the review of Haerle et al. [5]. Studies of SPECT-
CT in SLNB, which included different locations of primary
tumors, found especially advantages for tumors with close
proximity to the SLN and complex lymphatic regions which
is the case in the head-and-neck region [6].
The aim of this present study is to determine the added
value of SPECT-CT to the planar dynamic and static
lymphoscintigraphic images in patients with early stage oral
cancer.
Materials and methods
From June 2011 until January 2014, 66 consecutive patients
with early stage oral cancer and a clinically negative neck
(cT1–T2, N0) were retrospectively analyzed. During this pe-
riod, SLNB was performed as standard procedure in our insti-
tution therefore written informed consent was not obtained.
All patients underwent transoral excision and SLNB. The
SLNB was performed according to the EANM/SENT joint
practice guidelines [7]. In this article, we describe only the
imaging part of the procedure in our institution in detail, as
the entire procedure had been previously described [8].
All patients underwent the procedure in a 2-day protocol
with peritumoral injections of 99mTc labeled nanocolloidal al-
bumin (Nanoco l l ; GE Hea l t h ca r e , E indhoven ,
The Netherlands) in four quadrants at the closest proximity
of the primary tumor. The injections had a volume of 0.1–
0.2 ml each and the median dose of injected radioactivity
was 102 MBq (range, 91–111 MBq). To avoid spillage of
the radiocolloid, the patients will be required to perform a
mouthwash immediately after injection. No side effects due
to the colloidal injections were observed.
Planar and SPECT images were acquired with a SPECT-
CT gamma camera (Siemens, Erlangen, Germany). Planar
lymphoscintigraphy was started directly after injection of the
tracer. Planar images were acquired in dynamic mode
(128 × 128 matrix, 20 frames of 1 min) in anteriorposterior
projection and static mode (256 × 256 matrix, during 2 min) in
anteriorposterior and lateral projections. In addition to the
planar imaging, SPECT-CT scans had been routinely per-
formed in all patients without changing the patient’s position.
SPECT (matrix 128 × 128, non circular, 32 steps, 40 seconds
per step, slice thickness 4.8 mm) took 24 min, CT (40 mAs,
130 kV, slice thickness 1.5 mm) took approximately 5 min.
The SPECT images were reconstructed by filtered back
projection (FBP: Generalized Hanning, cut-off 0.90, alpha
0.5, no attenuation correction) and iterative reconstruction
(Iterative Flash3D with CT attenuation correction (CTAC):
six iterations, eight subsets, Gaussian filter 12). The CT study
was reconstructed with 5-mm slice thickness (Kernel B08s)
and in soft tissue setting with 2-mm slice thickness (Kernel
B30s). Reconstructions were obtained in transversal, sagittal,
and coronal planes.
Subsequently, the identified SLNs were anatomically cate-
gorized according to the levels of the neck as proposed by the
Committee for Head and Neck Surgery and Oncology of the
American Academy of Otolaryngology – Head and Neck
Surgery (AAO-HNS) [9]. The SLNs were marked on the pa-
tient’s skin using a 57Cobalt marker and confirmed using a
handheld gamma probe (Europrobe II; Eurorad, Strasbourg,
France).
In this retrospective analysis, we focused on the additional
value of the SPECT-CT imaging on the number of SLNs, their
localization, and the additional value of better topographical
orientation preoperatively. Exclusion of initially considered
SLNs on planar imaging due to SPECT-CT was also consid-
ered clinically relevant.
A clear visible and rapidly appearing lymph node was con-
sidered to be a SLN according to the definition of Morton
[10]. Less visible lymph nodes (especially in presence of a
clear SLN) were considered second or third echelon and had
not been marked on the skin. In this study, all images were
evaluated by a team consisting of a nuclear physician, a head-
and-neck surgeon, and an investigator. The team had to reach
consensus in every patient. All team members had experience
with at least 20 patients with SLNB imaging and early stage
oral cancer. First, the planar lymphoscintigraphic images
alone were interpreted, thereafter the team compared the pla-
nar imaging with the SPECT-CT and the potential additional
value had been assessed. Additional hotspots on SPECT-CT
that received direct drainage from the primary tumor were
considered as SLNs, while level or neck side was not relevant
for being an SLN. The additional hot spots found on SPECT-
CTwere considered also as SLNs if the intensity of uptake in
the additional lymph node was at least as hot as considered
SLNs on planar lymphoscintigraphy. If the additional hotspots
on SPECT-CTwere more proximal to the primary tumor com-
pa r e d w i t h o t h e r c on s i d e r e d SLNs on p l a n a r
lymphoscintigraphy, they were also scored as SLNs.
Additional caudal hotspots with low uptake, not increasing
in time, were considered to be second-echelon lymph nodes.
A caudal focus with a clearly visible connecting lymphatic
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vessel from a cranial SLN was also considered a second-
echelon lymph node [11]. There was no limit on the number
of SLNs.
A calculation of how many SPECT-CT scans are needed to
find one additional SLN was also performed, a so-called
Bnumber needed to SPECT-CT .^ This calculation is a varia-
tion on the well-known number needed to treat, which is the
inverse of the absolute risk reduction. This number needed to
SPECT-CT will be calculated by 100/percentage of patients
with (positive) additional SLNs on SPECT-CT.
Anatomical information by SPECT-CT was considered to
be important if the head-and-neck surgeon in the scoring team
would probably make a different (or more accurate) surgical
approach based on the additional information. If regional dis-
ease during follow-up occurred after a negative SLNB, the
procedure was considered as false negative.
Results
In this cohort of 66 patients, the identification rate of SLNs
was 98% (65/66). In one patient, no SLN could be identified
on either planar lymphoscintigraphy or SPECT-CT, however
this patient showed no metastasis in the untreated neck during
regular follow-up for almost 5 years. In 22% (14/65) of the
patients, 15 additional SLNs could be identified due to
SPECT-CT imaging. The additional SLNs related to other
identified SLNs had been found in the same (two SLNs),
adjacent (six SLNs) and non-adjacent (four SLNs) levels or
in the other neck side (three SLNs). One of these additional
SLNs could not be found intraoperatively. In the remaining 14
SLNs, metastases were present in two SLNs (13%). At least
one positive SLNwas found in ten patients and in two of these
patients (20%) the positive SLN had been identified due to the
addition of SPECT-CT. These two metastases (one
micrometastasis in level III ipsilateral (T1 floor-of-mouth tu-
mor) and onemacrometastasis in level II ipsilateral (T2 tongue
tumor)) were the only SLNs containing metastasis in the neck,
resulting in an upstaging rate of 3% (2/65 patients) (Fig. 1).
Five (100/22%) SPECT-CT scans are needed to identify one
additional SLN compared with planar lymphoscintigraphy.
This Bnumber needed to SPECT-CT^ is 34 (100/2.9%) for
identification of one additional SLN containing metastasis.
In contrast to these additional SLNs, in 8% (5/65) of the
patients, a hot spot was considered to be an SLN based on
planar lymphoscintigraphy but was not after SPECT-CT (e.g.,
injection spot rather than SLN in four patients). In 28% (18/
65) of the patients, the anatomic levels of the SLNs on
lymphoscintigraphic imaging had been changed with help of
the SPECT-CT imaging. In one patient, SPECT-CT identified
one additional SLN, but also one considered SLN on planar
lymphoscintigraphy could be scored as non-SLN. This results
in a full concordance rate according to the number and level of
SLNs between planar lymphoscintigraphy and SPECT-CT
imaging of 54% (35/65).
With respect to the location of the primary tumor, SPECT-
CT identified more additional SLNs in patients with floor-of-
mouth tumors compared with tumors of the tongue (42 vs.
13%, p = 0.07). In both tumor subsites, one additional SLN
showed metastasis and in each of these two tumor subsites
SLNB was considered as false negative in two patients
(Table 1).
Important additional anatomical information of the SLNs
preoperatively due to SPECT-CT imaging was observed in
3% of the patients (2/65), making a more accurate surgical
approach possible (Fig. 2). Obviously, in the rest of the pa-
tients, a better topographical orientation for the surgeon had
been provided by SPECT-CT compared with planar imaging,
but the reading team had the impression that SLNB could also
be successfully performed with planar lymphoscintigraphy
only.
Discussion
In this study of 66 patients with early stage oral cancer, we
retrospectively evaluated the additional value of SPECT-CT
compared to the conventional planar lymphoscintigraphy for
the detection of SLNs. To our knowledge, this is the largest
single-center study investigating the additional value of
SPECT-CT in oral cancer. In a multidisciplinary setting, both
imaging modalities were separately investigated, and in 22%
of the patients, additional SLNs were found on SPECT-CT
imaging. In 20% of the SLN-positive patients, the positive
SLN had been identified only with SPECT-CT. These addi-
tional positive SLNs result in an upstaging rate to a positive
neck of 3% in the total cohort, in other words we have tomake
34 SPECT-CT scans to identify one additional positive SLN.
These results are more or less comparable with some previ-
ously reported studies [12–15], but some other studies report
higher rates [16, 17]. A study with barely no additional SLNs
due to SPECT-CT had also been reported [18]. It is hard to
find a reasonable explanation for these differences in almost
comparable patient groups and comparable imaging modali-
ties [5]. One reason may be the difference in imaging proto-
cols throughout Europe with respect to the amount of injected
radioactivity and the time of injection related to the surgical
procedure (same- or 2-day protocols) [19]. Another explana-
tion can be the practice variation in defining SLNs on planar
lymphoscintigraphy as shown by Flach et al. [20]. In order to
perform consistent lymphoscintigraphic evaluation, defining
the SLNB concept is essential. There are many definitions of
the SLN and many articles discuss the subject. The definition
of Morton et al. [10], which says ‘a sentinel node is the first
draining lymph node on the direct lymphatic drainage path-
way from the primary tumor site’ best reflects the stepwise
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spread of cancer through the lymphatic system. However, this
is a theoretical concept, and does not always aid the clinician
in interpreting a lymphoscintigraphic scan as an individual
situation, because it is regularly not so clear-cut as this theory.
Describing how to interpret lymphoscintigraphic imaging
with a view to identify foci (hot spots) as SLN in a simple
and straightforward way is not easy. In a study on interobserv-
er agreement, many experienced observers correctly consid-
ered SLNs as the lymph nodes directly draining from the
injection site, and/or single radioactive nodes in a basin,
whereas other important criteria as uptake intensity, time of
appearance, relevance of neck side and level were rated
differently. Interobserver agreement can be influenced by a
number of factors. If a single focus is visualized, there will
be no disagreement. However, in a complex nodal basin as the
neck area, several foci are often visible. This harbors an in-
creased risk of not identifying the correct SLN and/or misin-
terpretation of second echelon nodes as SLNs [20]. In view of
the literature, it seems that despite the additional information,
SPECT-CT is not yet able to solve the problem of difficult
interpretation of SLNs.
The study of Haerle et al. [13] showed all their additional
SLNs in the same or adjacent levels as hotspots detected by
planar lymphoscintigraphy alone and they suggest that even
Fig. 1 SPECT-CTshows additional SLN level II on the left side (arrow).
Patient with a clinically T2N0 tongue tumor on the left side. a Planar
lymphoscintigraphy showed directly post-injection the injection spot (i)
but no SLNs, 1 h post-injection (b) two hotspots, judged as SLN level IA
right (1) and second echelon lymph node in level IV right (2). c, d, e
SPECT-CT showed an additional hotspot (arrow), considered as SLN
level II on the left side. Due to the high amount of uptake in level IV
right on SPECT-CT (2), exploration with the gamma probe was
performed during surgery. During surgery, three SLNs had been
identified (level IA right, level IV right, and level II left), all hot, not
blue. The SLN level II left contained a macrometastasis. A
complementary neck dissection (selective I–IV) had been performed
without additional metastasis on histopathological examination. No
evidence of disease during follow-up of 32 months was observed
Table 1 Additional SLNs due to
SPECT-CT imaging according to
tumor localization





Tongue 39 5 (13%) 1 2
Floor of mouth 19 8 (42%) 1 2
Buccal mucosa 4 1 (25%) 0 0
Other 3 0 0 0
Total 65 14 (22%) 2 4
SLNs sentinel lymph nodes
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necks without hotpots should be explored with the gamma
probe intraoperatively, based on the fact that the gamma probe
identified SLNs in patients without hotpots on imaging. In
contrast to their study, we found seven additional SLNs in a
non-adjacent level or even in the other neck side compared to
planar lymphoscintigraphy. However, we still found the
(dynamic) planar lymphoscintigraphy of additional value in
differentiating SLNs and second-echelon nodes, especially
using the criterion of rapidly emerging hot spots. Therefore,
we recommend a combination of planar static and dynamic
imaging followed by SPECT-CTas the currently best imaging
procedure for SLNB.
We hypothesized that we could find additional SLNs due to
SPECT-CT, especially in patients with SLNs in close proxim-
ity to the primary tumor, as is the case for SLNs in level I with
a primary tumor in the floor of mouth. Indeed, in five patients,
additional SLNs had been identified in level I; however, four
of these patients had a tongue tumor and only one had a floor-
of-mouth tumor. In addition, in four patients (two tongue tu-
mors, two floor-of-mouth tumors) a hot spot considered to be
a SLN could be identified as injection spot rather than SLN in
level I by SPECT-CT. We found a trend for more additional
SLNs in floor-of-mouth tumors compared with tongue tu-
mors, also resulting in a lower number needed to SPECT-CT
(not presented).
Despite our experience with SLNB in oral cancer, we re-
port a relatively high number of false-negative patients in this
study. In this small cohort of 19 floor-of-mouth tumors, two
false-negatives were present, compared to two false-negatives
in 39 tongue tumors. In one patient with a left-sided floor-of-
mouth tumor, the initially found SLN was located in level I on
the right side; then this patient returned with a metastasis in
level I on the left side 6 months after SLNB, which had been
probably missed on the planar lymphoscintigraphy and
SPECT-CT. The other false-negative patient with a floor-of-
mouth tumor had a regional metastasis in level III 13 months
after SLNB. Both patients are alive with no evidence of dis-
ease for more than 2.5 years. Both patients with a tongue
tumor and false-negative SLNB had regional metastasis in
level II ipsilateral, approximately 1 year after SLNB. One
patient is alive with no evidence of disease for 3 years, and
one patient was lost to follow-up.
In our opinion, SPECT-CT did not solve the problems of
the lower accuracy in patients with floor-of-mouth tumors,
despite the higher number of additional identified SLNs due
to SPECT-CT. The finding that additional SLNs were mainly
found in other levels than level I suggests that the Bshine
through phenomenon^ remains the most common problem
in floor-of-mouth tumors. Other new technologies and proce-
dures, e.g., superselective neck dissection of level I, 99mTc-
tilmanocept, fluorescence-guided SLNB, and PET/CT
lymphoscintigraphy with 89Zr-nanocolloidal, seem promising
to improve the accuracy of the SLNB in floor-of-mouth tu-
mors [21–25].
It should be clear that SPECT-CT allows better anatomical
information for the surgeon preoperatively in all cases. In two
patients, our team had determined this information of evident
importance. We described a sublingual node on SPECT-CT,
wh i c h h a d b e e n s c o r e d a s l e v e l I o n p l a n a r
lymphoscintigraphy (Fig. 2). Sieira-Gil et al. [15] had also
Fig. 2 Example of better
topographical orientation. Patient
with a clinically T2N0 floor-of-
mouth tumor on the right side. a
On the planar
lymphoscintigraphy, the hotspot
is clearly visible (arrow),
considered to be a sentinel lymph
node in level I. Also, a less-visible
hot spot was observed (dashed
arrow), considered to be a second
echelon node. bLateral projection
of the planar lymphoscintigraphy
on the right side of the neck with
the same intense hotspot in level I
(arrow) and very weak uptake in
the considered second echelon
node (dashed arrow). c, d, e
SPECT-CT shows a hotspot just
behind the mandible (white
arrow) with close relationship to
the injection spot of the primary
tumor (i) and was actually
considered as a sublingual node
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found sublingual SLNs by SPECT-CT (two cases), which had
not been detected by planar lymphoscintigraphy. Due to the
better topographical orientation, the anatomical levels of the
SLNs had been changed in 28% of the patients and better
delineation against surrounding tissues could be done.
Nevertheless, it still remains difficult to determine the extent
to which SPECT-CT influences the surgical approach related
to planar lymphoscintigraphy particularly due to the use of the
handheld gamma probe just before incision. To get more in-
sight in this additional value, the surgical procedure should be
planned blinded to the results of the SPECT-CTand replanned
after revealing the SPECT-CT. Our study suggests that
SPECT-CT is helpful preoperatively and probably because
of the better anatomical orientation surgery could be per-
formed more safely than with planar lymphoscintigraphy
alone.
We report a relatively low concordance rate of 54% be-
tween planar lymphoscintigraphy and SPECT-CT in compar-
ison to the concordance rate of 81% of Haerle et al. [13].
However, they only report a concordance rate according to
number of hotpots on both imaging modalities, where we also
include changes of anatomical levels of the hotspots in this
rate.
Nowadays, SLNB for early stage oral cancer is
gaining more acceptance worldwide and has recently
been included in many guidelines. In the beginning,
SLNB had been reported to be safe with planar
lymphoscintigraphy alone, but, in general, all studies
published in the last 5 years had performed SLNB with
SPECT-CT in addition to planar imaging despite only
moderate evidence in reported literature so far.
We conclude that SPECT-CT after static and dynamic pla-
nar lymphoscintigraphic imaging has the potential to detect
more (22%) SLNs than planar lymphoscintigraphy alone, es-
pecially in patients with floor-of-mouth tumors, resulting in an
upstaging rate of 3% in all patients. In 20% of the patients with
at least one positive SLN, the only positive SLN was detected
due to the addition of SPECT-CT. Moreover, SPECT-CT pro-
vides better topographical orientation for the surgeon preop-
eratively. We recommend the addition of SPECT-CT in SLNB
for patients with early stage oral cancer, however other im-
provements are still mandatory to increase the accuracy of this
procedure.
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